Drug Evaluation Committee Multivariate Meta-Analysis and Alternative Endpoints in Medical Technology Evaluation
Data Science Subcommittee
May 2023
In Japan, a cost-effectiveness evaluation system was fully introduced in 2019 for the purpose of adjusting the prices of pharmaceuticals and medical devices. In examining cost-effectiveness, it is necessary to evaluate the additional usefulness of the technology to be evaluated in comparison with the comparator technology through a systematic review. If there is no evidence of direct comparison between the technology under evaluation and the comparison control technology, indirect comparison by network meta-analysis, etc., should be conducted. This task force published a report "Introduction to the NICE TSD Evidence Synthesis series based on Technical Support Document (TSD) No. 1 to 7 published by the Decision Support Unit of NICE, UK: Network Meta-Analysis" based on the Technical Support Document (TSD) Nos. 1-7 published by the Decision Support Unit of the NICE, and released in 2020. This report introduces its follow-up, TSD 20, which deals with multivariate meta-analysis that extends meta-analysis to multiple endpoints within the framework of Bayesian flow, and its application to methodologies related to alternative endpoints. These approaches are useful for medical technology evaluation of new drugs when evidence for alternative endpoints is available but not for the true endpoints, and for utilizing more evidence when building economic models using multiple endpoints. The approach is useful for the medical technology evaluation of new drugs at the stage where the evidence of true endpoints is not obtained.
Committee on Drug Evaluation, Japan Pharmaceutical Manufacturers Association
Data Science Subcommittee 2022 Ongoing Task Force 7
Multivariate Meta-Analysis and Alternative Endpoints in Health Technology Assessment (1.5 MB)
Deliverables of the Drug Evaluation Committee Return to list of all deliverables